← Leaderboards
Tor C. Savidge
Methodist Hospital Research Institute
$8,331,421
Attributed
$16,717,684
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,756,096 · 9
By mechanism
P01$14,788,685 · 2
U01$7,916,381 · 1
R01$4,939,415 · 3
R21$808,188 · 2
R41$303,427 · 1
Top collaborators
- Cesar Augusto Arias5 shared
- Robert A Britton5 shared
- Kevin W Garey5 shared
- Samuel A Shelburne5 shared
- Joe Sorg5 shared
- Kara Gross Margolis4 shared
- Larissa Takser4 shared
- Ardesheer Talati4 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Cesar Augusto Arias$18,609,748
- Samuel A Shelburne$8,822,845
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionPathogenMicrobiomeMicrobialInnovationClostridium DifficileInfectionBaseGut MicrobiotaHigh RiskMicrobiotaChildPredispositionNovel TherapeuticsAntimicrobialCohortIntestinesFecesMetagenomicsRisk FactorsHospitalsAdultLinkAntimicrobial Resistance
Grant awards (31)
Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)$2,377,848
P01 · FY2025 · AI
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen$532,800
P01 · FY2025 · AI · contact PI
Development of sIgA from human milk as a therapeutic for Inflammatory bowel disease$303,427
R41 · FY2025 · DK
Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)$2,406,527
P01 · FY2024 · AI
A Prospective Study Examining the Role of Gestational SSRI Exposure in the Development of Functional Gastrointestinal Disorders$582,005
R01 · FY2024 · DK
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen$532,800
P01 · FY2024 · AI · contact PI
PATHWAYS TO NEW BIOMARKERS IN RECURRENT ABDOMINAL PAIN IN CHILDREN$472,251
R01 · FY2024 · NR · contact PI
A Prospective Study Examining the Role of Gestational SSRI Exposure in the Development of Functional Gastrointestinal Disorders$606,228
R01 · FY2023 · DK
Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)$2,411,532
P01 · FY2022 · AI
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen$651,255
P01 · FY2022 · AI · contact PI
A Prospective Study Examining the Role of Gestational SSRI Exposure in the Development of Functional Gastrointestinal Disorders$650,155
R01 · FY2022 · DK
Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)$2,378,848
P01 · FY2021 · AI
A Prospective Study Examining the Role of Gestational SSRI Exposure in the Development of Functional Gastrointestinal Disorders$696,871
R01 · FY2021 · DK
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen$539,460
P01 · FY2021 · AI · contact PI
Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)$2,463,657
P01 · FY2020 · AI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,486,851
U01 · FY2020 · AI · contact PI
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen$493,958
P01 · FY2020 · AI · contact PI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,482,023
U01 · FY2019 · AI · contact PI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,952,767
U01 · FY2018 · AI · contact PI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,494,740
U01 · FY2017 · AI · contact PI
Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection$1,500,000
U01 · FY2016 · AI · contact PI
Allosteric therapy of the Clostridium difficile toxins$393,250
R01 · FY2016 · AI · contact PI
Allosteric therapy of the Clostridium difficile toxins$393,250
R01 · FY2015 · AI · contact PI
Metabolome-Based Biomarkers and Neutraceuticals in Clostridium Difficile Infection$196,625
R21 · FY2015 · DK · contact PI
Allosteric therapy of the Clostridium difficile toxins$393,250
R01 · FY2014 · AI · contact PI
Metabolome-Based Biomarkers and Neutraceuticals in Clostridium Difficile Infection$235,950
R21 · FY2014 · DK · contact PI
Allosteric therapy of the Clostridium difficile toxins$369,655
R01 · FY2013 · AI · contact PI
Allosteric therapy of the Clostridium difficile toxins$274,775
R01 · FY2012 · AI · contact PI
Allosteric therapy of the Clostridium difficile toxins$107,725
R01 · FY2012 · AI · contact PI
S-nitrosoglutathione regulation of intestinal barrier function in Crohn's disease$186,863
R21 · FY2010 · DK · contact PI
S-nitrosoglutathione regulation of intestinal barrier function in Crohn's disease$188,750
R21 · FY2009 · DK · contact PI